BCL2A1 Protein, Human, Recombinant (His)

Catalog No. TMPY-04936

B-cell lymphoma 2-related protein A1 (BCL2A1) is a member of the BCL-2 family of anti-apoptotic proteins that confers resistance to treatment with anti-cancer drugs. Immunohistochemical expression of Wnt11 and BCL2A1 in complete moles and normal villi. Bcl2 family proteins control mitochondrial apoptosis and its members exert critical cell type and differentiation stage-specific functions, acting as barriers against autoimmunity or transformation. Anti-apoptotic Bcl2a1/Bfl1/A1 is frequently deregulated in different types of blood cancers in humans but its physiological role is poorly understood as quadruplication of the Bcl2a1 gene locus in mice hampers conventional gene targeting strategies. In a physiological context, BCL2A1 is mainly expressed in the hematopoietic system, where it facilitates survival of selected leukocytes subsets and inflammation. However, BCL2A1 is overexpressed in a variety of cancer cells, including hematological malignancies and solid tumors, and may contribute to tumor progression. The development of small molecule inhibitors of BCL2A1 may be a promising approach mainly to sensitize tumor cells for apoptosis and thus improve the efficiency of anti-cancer therapy.

BCL2A1 Protein, Human, Recombinant (His)

Catalog No. TMPY-04936

Pack Size	Price	Availability	Quantity
200 μg	$904	7-10 days

Bulk & Custom

Add to Cart

Questions

QWhat’s ED50?

AEffective dose 50 (ED50）refers to the dose of a drug that produces a specific effect in 50% of the population that has been administered that dose.

QDoes the compound differ in any way when it is in the form of hydrochloride or sulfate ions? What is the difference between the salt form and the free form?

AThe molecules in salt and non-salt forms exhibit the same activity, and they have consistent effects in biological experiments. Their activity and usage are identical. The only difference lies in their salt forms, which may result in variations in physical properties such as solubility. It is recommended to choose based on solubility and experimental requirements.

QWhat’s Ki?

AInhibitory consent (Ki) reflects the strength of inhibitor binding to the target, corresponding to the concentration of free inhibitor when 50% of the target is bound by the inhibitor.

QHow to recommend specific or broad-spectrum inhibitors for a target? What is the difference between specificity and nonspecificity?

AInhibitors can be classified into two types based on specificity: broad-spectrum (pan) and selective inhibitors. Pan inhibitors are inhibitors of a particular target that have inhibitory effects on all subtypes or members of the entire family. Selective inhibitors have particularly high inhibitory rates or specific inhibitory effects on a subtype of a protein kinase or a member of a family of proteins. The evaluation of the inhibitory efficiency of an inhibitor generally relies on the IC50 value, with lower IC50 values indicating higher inhibitory efficiency. We recommend considering the above characteristics comprehensively when selecting inhibitors, and you can also contact our technical team for recommendations on relevant inhibitors.

QWhat’s IC50?

AHalf-maximal inhibitory concentration (IC50) refers to the concentration of the inhibitor which is required to inhibit a given biological or biochemical function by half.

Biological Activity	Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
Description	B-cell lymphoma 2-related protein A1 (BCL2A1) is a member of the BCL-2 family of anti-apoptotic proteins that confers resistance to treatment with anti-cancer drugs. Immunohistochemical expression of Wnt11 and BCL2A1 in complete moles and normal villi. Bcl2 family proteins control mitochondrial apoptosis and its members exert critical cell type and differentiation stage-specific functions, acting as barriers against autoimmunity or transformation. Anti-apoptotic Bcl2a1/Bfl1/A1 is frequently deregulated in different types of blood cancers in humans but its physiological role is poorly understood as quadruplication of the Bcl2a1 gene locus in mice hampers conventional gene targeting strategies. In a physiological context, BCL2A1 is mainly expressed in the hematopoietic system, where it facilitates survival of selected leukocytes subsets and inflammation. However, BCL2A1 is overexpressed in a variety of cancer cells, including hematological malignancies and solid tumors, and may contribute to tumor progression. The development of small molecule inhibitors of BCL2A1 may be a promising approach mainly to sensitize tumor cells for apoptosis and thus improve the efficiency of anti-cancer therapy.
Species	Human
Expression System	E. coli
Tag	N-His
Accession Number	Q16548-1
Synonyms	HBPA1,GRS,BFL1,BCL2L5,BCL2 related protein A1,ACC-2,ACC2,ACC-1,ACC1
Construction	A DNA sequence encoding the human BCL2A1 (NP_004040 ) (Met1-Ser152) was expressed with a polyhistidine tag at the N-terminus. Predicted N terminal: Met 1
Protein Purity	> 85 % as determined by SDS-PAGE.
Molecular Weight	19.7 kDa (predicted)
Endotoxin	Please contact us for more information.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
Reconstitution	A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, Lyophilized powders are shipping with blue ice.
Research Background	B-cell lymphoma 2-related protein A1 (BCL2A1) is a member of the BCL-2 family of anti-apoptotic proteins that confers resistance to treatment with anti-cancer drugs. Immunohistochemical expression of Wnt11 and BCL2A1 in complete moles and normal villi. Bcl2 family proteins control mitochondrial apoptosis and its members exert critical cell type and differentiation stage-specific functions, acting as barriers against autoimmunity or transformation. Anti-apoptotic Bcl2a1/Bfl1/A1 is frequently deregulated in different types of blood cancers in humans but its physiological role is poorly understood as quadruplication of the Bcl2a1 gene locus in mice hampers conventional gene targeting strategies. In a physiological context, BCL2A1 is mainly expressed in the hematopoietic system, where it facilitates survival of selected leukocytes subsets and inflammation. However, BCL2A1 is overexpressed in a variety of cancer cells, including hematological malignancies and solid tumors, and may contribute to tumor progression. The development of small molecule inhibitors of BCL2A1 may be a promising approach mainly to sensitize tumor cells for apoptosis and thus improve the efficiency of anti-cancer therapy.

BCL2A1 Protein, Human, Recombinant (His)

BCL2A1 Protein, Human, Recombinant (His)

Product Information

Dose Conversion

References

Calculator

Tech Support

Keywords